melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) cDNA in a nonviral expression vector was inserted into MDA-MB-231 (human breast cancer), M21 (human melanoma), B16 (murine melanoma), and P815 (mastocytoma) cells by particle-mediated gene transfer.
|
10078967 |
1999 |
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
|
11061616 |
2000 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF, IL-12, and B7-2 genes can be transferred to human glioma and melanoma cell cultures efficiently by use of our retroviral vectors.
|
11950413 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
|
16713660 |
2006 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adjuvant use of sequential GM-CSF and IL-2 +/- autologous vaccine was well tolerated with good patient compliance and seemed to benefit high-risk patients with surgically resected melanoma.
|
18593361 |
2008 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An oncolytic herpes simplex virus engineered to replicate selectively in tumor cells and to express granulocyte-macrophage colony-stimulating factor (GMCSF) was tested as a direct intralesional vaccination in melanoma patients.
|
19915919 |
2010 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As described in this protocol, fresh human sarcoma and melanoma specimens can be transfected with the GM-CSF DNA-coated gold particles with subsequent production of biologically active GM-CSF protein.
|
9143914 |
1997 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
|
30450100 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
|
31171039 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.
|
10930096 |
2000 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
|
28536308 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
|
12396624 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
|
31620131 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an aggressive B16-F10 murine melanoma model, we evaluated the effectiveness and antitumor mechanisms triggered by a surgery adjuvant treatment that combined a local suicide gene therapy (SG) with a subcutaneous genetic vaccine (Vx) composed of B16-F10 cell extracts and lipoplexes carrying the genes of human interleukin-2 and murine granulocyte and macrophage colony stimulating factor.
|
24973616 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we constructed a targeted oncolytic vaccinia virus of Tian Tan strain Guang9 (VG9) expressing murine GM-CSF (VG9-GMCSF) and evaluated the antitumor effect of this recombinant vaccinia virus in a murine melanoma model.
|
26803055 |
2016 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
|
10505851 |
1999 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Most notably, talimogene laherparepvec (T-VEC), a genetically engineered oncolytic herpesvirus-expressing granulocyte macrophage colony stimulating factor, was recently approved for the treatment of melanoma, representing the first OV to be approved by the FDA as an anticancer therapy in the US.
|
28589085 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF) and is approved for the treatment of melanoma and has shown therapeutic activity in murine tumors known to express high levels of STING.
|
31143509 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The fine specificity of the TIL line PM2-B2 restricted by HLA-A1 was further characterized by evaluating specific granulocyte-macrophage colony-stimulating factor release in response to MHC class I-eluted peptides derived from HLA-A1(+) melanoma cell lines.
|
9816095 |
1996 |
melanoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The HLA-A0201 presented melanoma-associated MART-1/Melan-A derived peptide AAGIGILTV was employed to assess the impact of such position-97 mutations on HLA-A2 in peptide binding measured in an HLA-A2 reconstitution assay and presentation to AAGIGILTV-specific polyclonal or clonal T lymphocytes as measured by cytotoxicity, or interferon (IFN)-gamma and granulocyte/ macrophage colony-stimulating factor (GM-CSF) secretion.
|
8921947 |
1996 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to determine the safety and antitumor activity of an autologous GM-CSF-secreting melanoma cell vaccine that was engineered ex vivo with recombinant replication-incompetent adenovirus harboring a human GM-CSF gene (Adv/hGM-CSF).
|
11676397 |
2001 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the tumor specificity, cytotoxicity and the antitumor activity of two conditionally replicating oncolytic adenoviruses, SKL001 and SKL002, which expressed granulocyte macrophage colony-stimulating factor (GM-CSF) or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody, respectively, and determine their antitumor efficacy in A549 lung tumor model, B16F10 mouse melanoma tumor model and CMT-64 mouse small lung carcinoma tumor model.
|
25034886 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS.
|
29414294 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have transfected human melanoma cell line 518A2 with the cDNA encoding interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), and compared cytokine-producing clones for their ability to induce melanoma-specific cytotoxic T lymphocytes (CTL) from autologous peripheral blood mononuclear cells (PBMC) in vitro.
|
9336741 |
1997 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the development of binding and neutralizing antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients receiving prolonged therapy with GM-CSF as adjuvant therapy of melanoma and the impact of these antibodies on biological effects.
|
25286079 |
2017 |